Encapsulation of active pharmaceutical ingredients in lipid micro/nanoparticles for oral administration by spray-cooling by Favaro-Trindade, Carmen S. et al.
pharmaceutics
Review
Encapsulation of Active Pharmaceutical Ingredients in Lipid
Micro/Nanoparticles for Oral Administration by Spray-Cooling
Carmen S. Favaro-Trindade 1,*, Fernando E. de Matos Junior 1 , Paula K. Okuro 1 , João Dias-Ferreira 2 ,




de Matos Junior, F.E.; Okuro, P.K.;
Dias-Ferreira, J.; Cano, A.; Severino,
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8 CEB—Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
* Correspondence: carmenft@usp.br (C.S.F.-T.); aleksandra.zielinska@igcz.poznan.pl (A.Z.);
eliana.souto@ceb.uminho.pt (E.B.S.)
Abstract: Nanoencapsulation via spray cooling (also known as spray chilling and spray congealing)
has been used with the aim to improve the functionality, solubility, and protection of drugs; as well
as to reduce hygroscopicity; to modify taste and odor to enable oral administration; and many times
to achieve a controlled release profile. It is a relatively simple technology, it does not require the
use of low-cost solvents (mostly associated to toxicological risk), and it can be applied for lipid raw
materials as excipients of oral pharmaceutical formulations. The objective of this work was to revise
and discuss the advances of spray cooling technology, with a greater emphasis on the development
of lipid micro/nanoparticles to the load of active pharmaceutical ingredients for oral administration.
Keywords: spray chilling; congealing spray; spray cooling; lipid nanoparticles; oral drug delivery
1. Introduction
Encapsulation technology has stood out for decades to solve the limitations encoun-
tered in the delivery of active pharmaceutical ingredients (APIs), food ingredients, cosmet-
ics, veterinary, hygiene, and cleaning products, among others. Among the most popular
technologies used in the production of delivery systems for APIs, coacervation, solvent
evaporation, solvent emulsion, ionic gelation, extrusion, high-pressure homogenization,
spray drying, and spray cooling (also called spray congealing and spray chilling) have
been particularly successful.
The spray cooling encapsulation technique consists of the preparation of a solution,
dispersion, or emulsion of the APIs, followed by its atomization in a chamber in which
cold air or liquid nitrogen is also injected [1,2]. Under these conditions, the API solidifies
instantly, resulting in spherical particles, insoluble in water, and with a size range (micro-
or nano-sized) governed by the configuration of the device used for atomization.
As encapsulating materials, natural, semi-synthetic, or synthetic mixtures are used,
most often of lipid nature. Acids and fatty alcohols, triglycerides, and waxes with a high
melting point are the most commonly used lipid materials for the loading of APIs in
micro/nanoparticles by spray-cooling [3]. Such materials have been intensively used as
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pharmaceutical excipients, as they are low-cost products and are well tolerated physiologi-
cally; in addition, triacylglycerols are sensitive to lipases and have high biocompatibility,
which minimizes the risks of acute and chronic toxicity [3–5].
The spray cooling technique is very convenient to encapsulate APIs, as it is a low-
cost process; it is easy to scale up; and it is a non-stop, continuous approach and does
not need organic solvents. The use of high temperatures may, on the other hand, be a
limitation when thermosensitive APIs are to be processed, besides the risk of reduced
encapsulation efficiency and expulsion of material from the chamber, thus reducing the
yield of production.
There is no consensus in the literature regarding the nomenclature of the encapsulation
technique by spray chilling, sometimes considered the synonym of spray cooling [6] and
spray congealing [7–10]. With respect to spray chilling and cooling, the terms are usually
used taking into account the melting point of the material selected as matrix. Thus,
spray chilling is the process in which the encapsulating materials have a melting point
between 32 and 42 ◦C, whereas in spray cooling, the encapsulation material usually has
a higher melting point, between 45 and 122 ◦C [11–14]. The term spray congealing is
used indiscriminately regardless of the melting temperature [9,15]. However, the lack of
consensus on terminology does not overshadow the unique importance of this technology
concerning encapsulation.
Several publications are available in the specialized literature describing the prepara-
tion of lipid micro/nanoparticles by the spray cooling technique for different purposes,
which include changing the dissolution profile of poorly soluble APIs, prolonged release of
APIs with a short half-life, alteration of taste and odor, increased stability of photosensi-
tive ingredients, and encapsulation of bioactive proteins and peptides [16,17]. In a more
recent approach, the spray cooling technique has been used for the production of lipid
micro/nanoparticles for oral administration of APIs. However, not a single work has been
found where these data have been compiled to provide an overview of the importance and
the level of progress of this technique in the area, which is the primary aim of this review.
2. Encapsulation by Spray-Cooling
Spray-cooling consists of two stages. The first requires the addition of the API to be
encapsulated to the matrix material, usually a melted lipid or an oil-in-water emulsion (in
the case of hydrophilic APIs). The second step is the atomization of the lipid phase in the
form of droplets, usually by a heated atomizer nozzle, to maintain adequate temperature;
to avoid recrystallization of the lipid compounds; and, when this nebulized material comes
into contact with a cooled environment (chamber with cold air injection or liquid nitrogen),
with temperature below the melting point of the lipid, heat transfer occurs between the lipid
and the cold air, leading to the solidification of the matrix and resulting in the formation of
the particles [10,18].
The residence time of the sprayed droplets in the cooling chamber is short. The
particles are collected in a container below the cooling chamber, while the very fine particles
are transported by air to a cyclone, where they are collected in another container (Figure 1).
The production of particles by this method has been applied in several segments, such
as pharmaceuticals, cosmetics, agricultural, veterinary, and food industries [19]. Like spray
drying, the spray cooling encapsulation process has been reported for food ingredients,
APIs, and flavourings [20].
Numerous applications for solid lipid particles have been investigated, for example,
to modify odor and taste [21,22]; to protect the loaded material from conditions such as
pH, enzyme action, moisture, oxygen, light, and optimization of the dissolution of poorly
soluble APIs; to modify the release profile of loaded API; and to improve flow properties,
handling, and appearance, among other purposes [10,23,24].
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The process is widely used in the pharmaceutical field for the development of special-
ized API delivery systems [7,23,24]. In this context, spray congealing encapsulation may be
related to the increased stability of sensitive compounds, such as small peptides like insulin,
and poorly soluble drugs. The process also refers to the reduction of hygroscopicity, the
alteration of undesirable flavours, and the alteration of the APIs’ release profile [25,26]. The
generated product is insoluble and, generally, is released from the matrix in a controlled
fashion until the melting point of the lipid matrix is reached [27]. The appropriate selection
of the matrix material is crucial, as encapsulation can alter the properties of the API either
by reducing its hygroscopicity and/or by increasing its stability [21].
Critical steps of the process include (i) atomizing the molten mixture (encapsulating
agent and filling) and (ii) solidifying. The first refers to the disintegration of the melted
mixture into small particles [28], while solidification is related to the process of recrystal-
lization of the melted material into a solid by cooling it. From an operational point of view,
insufficient cooling of the droplets leads to their agglomeration and/or adhesion on the
surface of the chamber, an event that affects the morphology, the process itself, and other
properties of the micro/nanoparticles.
Spray cooling is very similar to spray drying, mainly differing with respect to the
direction of the energy flow involved. In the case of spray drying, energy is applied to
the droplets, forcing the solvent to evaporate, while in the spray cooling, the energy is
removed from the droplets, forcing the loaded API to solidify [18]. Thus, spray cooling
can be regarded as a fusion between hot-melt technology (coating or agglomeration) and
spray drying. Table 1 shows the differences between spray cooling and spray drying in
several aspects. The initial configuration of spray cooling is very similar to spray drying;
however, in contrast to spray cooling, the spray drying process enables the generation of
small particles by rapid solvent evaporation from the surface of droplets. Conventional
spray dryers can be used as spray coolers containing cold air. The instrument consists
of two main parts, namely (i) a cooling chamber and (ii) the atomizer (Figure 1). For an
efficient process, it is recommended that the dispersion of the melted mixture occurs within
a very narrow melting temperature range, so that the particles are also solidified during
spraying [29,30].
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Table 1. Differences between spray cooling and spray drying techniques.
Parameters Spray Drying Spray Chilling
Energy flux Energy applied to the droplets, forcingevaporation of the medium
Energy removed to the droplets, forcing the
medium to solidify
Equipment Feed tubes without heating Heated feed tubes (to prevent solidification)
Flow in the equipment chamber Hot air Cold air or liquid nitrogen
Average particle size 5–150 µm 20–200 µm
Release mechanism Dissolution Difussion, heating
Morphology of particle Particle with irregular geometry and poroussurface due to solvent evaporation
Dense, spherical and smooth surface (absence of
the evaporation effects of the solvent)
Coating Water-soluble polymers Waxes, fatty acids, water-soluble andwater-insoluble polymers, monomers
Food ingredients
Vitamins, flavors, starter cultures,
carotenoids, oils and fats,
enzymes, acidulants
Ferrous sulphate, vitamins, minerals, acidulants
Steps in the process









The variables with greater emphasis on this process include (i) the melting temperature
of the lipid compounds; (ii) the temperature of the chamber; (iii) the temperature of the
atomization air; (iv) the atomization air pressure; and (v) the feed flow of the melted
mixture [10].
The critical conditions to obtain uniform and small particles include the low viscosity
of the melted dispersion and the high atomization speed. It is suggested that the ideal
viscosity is around 24 cP at 55 ◦C [29].
The performance of the spray cooler strictly depends on the atomization efficiency
of the melted mixture. The efficiency of the atomization process, on the other hand, is
directly associated with the different types of devices that can perform the atomization
function. Such devices are atomizers, which can be of different types such as pressure
nozzles, rotary or centrifugal, double fluid, and ultrasonic nozzles [10,18]. All available
atomizers have recurring characteristics, such as the difficulty in nebulizing mixtures with
higher viscosity. The conditions of supply and pressure used can be inferred under the
homogeneous distribution of the particle.
Some studies have been carried out with the aim to investigate the influences of the
process parameters. Maschke et al. found that increasing the atomization pressure from 5
to 6 bar decreases the size of the particles obtained by spray chilling [8]. Another important
variable that influences the particle size is the viscosity of the feed mixture, which can be
regulated through temperature or through the type and quantity of dispersed solids. Low
viscosity (seen for higher temperature) results in smaller particle sizes [8], while the higher
viscosity (owing to the addition of solids, for example) results in larger particle sizes [9].
The molten mixture, which will be the feed stream, has a characteristic solidification curve.
When the atomized particles come into contact with the cooling medium, the material cools
down to its solidification temperature. Thereafter, the temperature remains constant during
the release of the product’s heat. Stable solid particles are then formed. Some products
do not have a well-defined solidification point, with a phase change occurring over a
range of temperatures, or the product may also turn into an amorphous solid without
releasing the solidification heat, as a non-crystalline formation occurs. The particles can
also be cooled below the solidification temperature, before hardening. The data on the
physical properties of the melted material and its behaviour during the solidification
Pharmaceutics 2021, 13, 1186 5 of 14
process are important to define the design of the cooling chamber and the selection of the
atomizer, as well as to determine whether the cooling should be carried out in one or two
steps [31]. The atomized material goes through three cooling stages: (i) cooling the liquid;
(ii) solidification; and, finally, (iii) cooling of the solid particles. The temperature of the
nebulized droplets decreases as they come into contact with cold air. Upon reaching the
solidification temperature, the droplets gradually solidify. As the newly solidified particles
have a higher temperature than the environment, they continue to lose heat until they
reach room temperature [10].
Another important aspect to ensure is the temperature control during the solidification
process of the lipid wall, as its maintenance avoids the polymorphism in fats, a factor that
directly affects the release profile of the loaded API. The lipid matrix can crystallize in
different polyphonic forms. For example, in the case of rapid cooling, the lipid is preferably
crystallized in an unstable form, α. On the other hand, when the cooling is slow, the
tendency is the appearance of the form β [32,33].
Several studies have investigated the performance and improvement of equipment
for the spray cooling technique, such as the use of pneumatic spray nozzles [9], compact
ultrasound [34], and ultrasonic atomizer to disperse the atomized particles [35], among
others. Ilić et al. studied the effect of some variables on the microencapsulation process
by spray chilling [10]. The authors concluded that both the feed rate and the atomization
pressure influence the final particle size. The higher the applied pressure, the smaller
the particle size obtained and vice versa. With regard to feeding, a high feeding capacity
increases the size of the particles, while, however, providing greater control of the particle
size that can be achieved by controlling the atomization pressure.
2.2. Morphological Characteristics of Particles
Regarding the physical structure, the particles produced by spray cooling are of the
matrix type, i.e., where the core or APIs are dissolved or dispersed in the crystallized lipid.
In general, the particles produced have a spherical shape, which facilitates their flow [10],
and are impermeable to water, but not resistant to it. These qualities are essential for a
good incorporation of the material, owing to the reduction of the surface tension between
the lipophilic surface of the particles and the aqueous environment where it will be added,
allowing the flow of particles in the food [29].
As the process does not involve solvent evaporation, commonly observed in other
techniques such as spray drying, the produced particles are usually dense and non-porous,
in addition to being mechanically resistant, remaining intact under stirring [29].
For the pharmaceutical industry, the characteristics of the obtained particles, such as
the smooth surface and mechanical resistance, are relevant as they improve the particles’
rheological behaviour, which is instrumental if they are aimed to fill, e.g., gelatine capsules
or compression matrix in tablets’ production [29]. An additional coating can be applied to
the microparticles obtained by spray cooling to ensure complete coverage of the particle
and eliminate unwanted interactions surrounding them, during storage [30]. The particle
size depends on several factors, such as (i) the filling material; (ii) the viscosity of the
molten mixture; (iii) the disk configuration; and (iv) the rotational speed. Reactively to the
operational configuration of the equipment, depending on the required particle size and
the melting characteristics of the material, there is an adequate drop height [36].
2.3. Encapsulating Agents
Lipids are interesting alternatives as matrix material, owing to their ability related to
the various morphological states such as, for example, emulsions, liposomes, and solid
micro/nanoparticles [37,38]. The features of these materials that make them suitable for
this purpose include (i) the ability to be stable under typical process conditions; (ii) the
ease of atomization; and (iii) the moderate melting temperature, aiming at minimizing
the degradation of the filling component [39]. Encapsulating materials can be divided, in
general, between hydrophilic and lipophilic. In the pharmaceutical area, the former include
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polyoxylglycerides, poloxamers, polyethylene glycol (PEG), and polyethylene glycol esters,
while lipophilics include beeswax; carnauba wax; cetearyl alcohol; cetyl palmitate; mono-,
di-, and triacylglycerols (glyceryl behenate, glycerin palmitate stearate, glycerin stearate,
glycerin palmitate); hydrogenated castor oil; microcrystalline wax; paraffin wax; stearic
acid; and stearic alcohol [40]. The appropriate selection of the matrix material directly
affects the modulation of the release of the encapsulated agent, and is decisive for the
dissolving behavior of the APIs. Lipophilic matrices should be used to control the release
of short half-life APIs, such as verapamil hydrochloride [41] and theophylline [42]. Hy-
drophilic materials should be used when the increase in the dissolution rate is achieved,
such as carbamazepine [26], diclofenac sodium [43], and praziquantel [44]. The proper
selection of the wall material is unique, as it affects several factors such as (i) the change
in the properties of the encapsulated APIs; (ii) the increase in stability; (iii) control of the
release profile; (iv) the change in unpleasant taste; and (v) the reduction of gastrointestinal
irritation, enabling viability in certain environments [8,26,45,46].
2.4. Release Mechanisms
Controlled release aims at modulating the release of encapsulated APIs, being one
of the most relevant properties made possible by microencapsulation. In response to
a specific stimulus, that is, after the occurrence of a certain event, the particles start to
release from its interior. The type and geometry of the core particles and, above all, of the
matrix material, define the mechanism of release from the particle. Processes that employ
hydrophilic matrix materials, in general, trigger a faster release of the nucleus, compared
with those that use lipid compounds (fats or waxes), which tend to delay the release; while
the hydrophilic materials release the API by diffusion, the release from lipophilic matrices is
governed by erosion [47]. The release of APIs from the particles obtained by spray cooling
occurs via erosion and leaching of the matrix. Some surfactants, depending on the type
and concentration, can drastically affect the release rate of the API from the matrix. One
study demonstrated that the addition of 4% of a non-ionic surfactant (sorbitan monooleate)
resulted in an increase in the release rate from the lipid matrix; however, increasing the
concentration of the surfactant to 10% led to a reduction in its release [30]. The release of
APIs from lipid micro/nanoparticles can also be activated by the temperature. While in
the release by matrix erosion, lipids are degraded by the action of lipases present in the
body that participate in lipid metabolism, in the release triggered by temperature, the API
is released responding to the change in temperature, affecting the physical state and the
rate of release of the internal material. In this context, two distinct concepts stand out. The
first is related to temperature sensitivity, relevant to materials that shrink or expand when
a critical temperature is reached, and the second is due to melt activation, related to the
melting of the wall material in response to the increase in temperature, such as is the case
of walls made up of a modified lipid or waxes [48].
In the case of vitamins, potentially oxidizable compounds, micro/nanoencapsulation
can, in addition to increasing stability, promote the alteration of possible flavours, or
strange odours. In this case, APIs must be released after ingestion, i.e., in the stomach or
intestine; for this purpose, lipid materials are generally used, although cellulose derivatives
and cross-linked proteins can also promote the enteric release [49].
Regarding the concept of release after ingestion, for the effects to be truly understood,
the microorganisms administered must remain alive when passing through the stomach,
as the acidic environment and the presence of oxygen are harmful [50]. Therefore, the syn-
chrony associated with the fact that lipid digestion (of the particle wall) occurs effectively
in the intestine, where probiotics must act, reflects the efficiency and essential condition of
using the technique.
The particles produced by this method may contain amounts of APIs that have not
been effectively encapsulated, and can be attached to the outside of the lipid matrix. This
situation leads to a high initial release of APIs, followed by a release that can occur through
processes such as osmotic force, diffusion (even if small) of the filling through the matrix,
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mechanical breaks, and fusion of the lipids that make up the matrix [6]. In the case of
lipid particles, there is an important caveat to be considered, as it is common to think
that the release of APIs occurs only after the fusion of the matrix fat. However, this is not
necessarily the only way that allows the release of APIs. As a significant number of APIs
are located on the surface of the particles and have direct access to the environment, some
burst release may occur. In addition, other factors influence the release kinetics, such as
(i) osmotic force, (ii) the slow diffusion of water through the imperfections of the particles,
and (iii) the mechanical rupture [6].
The use of surfactants directly affects the stability of solid lipid micro/nanoparticles.
Their choice depends on the compounds involved in the production of the micro/nanoparticles
as well as on the application of the final product [51,52].
The release profile of the APIs from the particles can also be influenced by changes in
lipid matrices, concentration and type of surfactant (such as the presence of the lipophilic
soy lecithin), and production parameters [53]. These surfactants are added to provide
greater stability to the particles, as they assist in the effective connection between the filling
and the matrix. Schubert et al. studied the incorporation of lecithin in the lipid matrix to
optimize the incorporation of the filling [54]. These authors observed that the incorporation
of APIs increased linearly with the increase in the concentration of lecithin present up to a
certain percentage, and this effect was attributed to the formation of micelles in the middle
of the lipid matrix, which promoted a higher loading of APIs. The addition of lecithin
would prevent the formation of very crystalline structures, increasing the retention of the
encapsulated material.
Zaky et al. studied the factors that affect the release kinetics of a protein encapsu-
lated in microparticles composed of triglycerides prepared using the spray congealing
technique [55]. The effect of particle size, particle morphology, and distribution on protein
release was investigated by confocal laser scanning microscopy. It was firstly seen that
water penetrates the microparticles and dissolves the incorporated protein, leading to the
formation of water-filled pores, which allow its diffusion out of the matrix. It was also
observed that the entry of water and the release of protein are strongly correlated processes,
and attention was paid to the importance of three-dimensional analysis, enabling greater
realism in the study of the distribution of the protein within the particle.
2.5. Advantages of the Process
Numerous advantages are associated with spray cooling, such as (i) speed, (ii) perfor-
mance, and (iii) the relatively low cost of the process itself. As it does not require the use of
water or organic solvents for its implementation, the elimination of residual solvents is not
necessary. In addition to being considered a fast, safe, and reproducible physical process, it
is also associated with an easy adjustment of particle size [42].
In the last two decades, spray cooling has also stood out on the environmental side,
being considered an environmentally correct technique, and when compared with other
procedures such as spray drying, it aims at lower energy and time consumption [56].
Another positive aspect is the ease of large-scale production, as it has the possibility of
being operated continuously, eliminating production steps [57].
Particles with large sizes and various shapes, high APIs’ encapsulation efficiency,
increased permeability characteristics through the oral mucosa, in addition to enabling
satisfactory and desirable inject ability, are also reported in the process [56,58].
2.6. Disadvantages of the Process
Although lipid micro/nanoparticles have advantages, there are also some associated
drawbacks, such as (i) the low encapsulation capacity of the material and (ii) the possibility
of expulsion from the interior by the matrix. During the storage time of the particles, many
lipid compounds applied for the formation of the dispersions can undergo changes, which
can affect the API, its stability, and/or its release profile [59]. To overcome this limitation,
the lipid material to be selected as a matrix compound should promote the solubility of
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the API, so that a higher loading can be achieved [60]. Besides, the selection of lipids that
recrystallize in a metastable form, able to retain this polymorphic form longer, will also help
to improve the loading parameters. Another limitation to be considered is the appropriate
choice of the material to be encapsulated, as it must be stable at the melting temperature of
its respective vector, which, in a way, restricts the API/matrix material relationship relevant
to the condition of the technique. For many APIs, the observed degradation temperature is
recurrently low, shortening the possibilities for the appropriate encapsulating agent. The
issue of the use of melted mixtures must also be considered, which requires operational
care, in order to avoid solidification and agglomeration of these, which compromises the
atomization efficiency and, consequently, the process.
The method has a drawback related to the fast cooling rates, which sometimes crystal-
lizes the lipid matrix in a certain polymorphic form, such as the α arrangement, which is
unstable, leading to the formation of disordered chains and/or with undesirable orientation
and, consequently, promoting low barrier properties, and during shelf life is organised
in more stable arrangements, resulting in the release of APIs [32,57]. Advantages and
disadvantages of spray cooling are listed in Figure 2.
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3. Encapsulation of APIs by Spray Cooling
Among the main techniques available for encapsulating APIs, the spray cooling
technique has attracted special attention over the past 10 years. The use of lipid materials as
matrix compounds, combined with the use of low temperatures and the absence of organic
solvents during the process, are some of the advantages that have driven research rs
to study th micro/nanoenca sulation of APIs by spray cooling as a way to overcome
limitations in the pharmaceutical i dustry and to create new applications. The process is
considered fast and of low cost, and has been tested for different purposes, which basically
include improving the dissolution profile of poorly soluble APIs, the development of
controlled release systems, the protection of APIs from adverse environmental conditions,
alteration of flavour, and encapsulation of proteins and peptides with therapeutic potential
by oral administration.
Pharmaceutics 2021, 13, 1186 9 of 14
3.1. Improvement of the Dissolution Profile
Several publications have reported promising results in improving the dissolution rate
of different APIs, including indomethacin [34], praziquantel [44], sodium diclofenac [43],
glimepiride [10], piroxicam [61,62], and carbamazepine [26,63]. The improvement of the
dissolution rate of these APIs has been obtained through the production of microparticles
from solid dispersions prepared with matrices from hydrophilic polymers [26]. In the
case of sodium diclofenac, for example [43], a 70% difference was found in the dissolution
rate of the loaded APIs with gelucire 50/13 compared with its pure form. Positive results
were also reported by Passerini et al. after assessing the dissolution rates of pure and
microencapsulated carbamazepine with gelucire 50/13 [26]. According to the authors, the
rate of dissolution of APIs in pure form was 40% after 10 min, and 80% in microencap-
sulated form. Later, these results were corroborated by other researchers who, using the
same encapsulating agent, found that the solubility of microencapsulated carbamazepine
increased 2.7 times in relation to pure APIs [63].
3.2. Sustained-Release Systems
By modifying the APIs’ release profile, several authors have developed pharmaceu-
tical formulations for prolonged release of APIs that have a short half-life. In this case,
unlike encapsulation aimed at enhancing the dissolution rate of APIs, the use of lipophilic
matrices is recommended [34]. Theophylline [35,42], fembunfen [35], felodipine [64], and
verapamil hydrochloride [41] are examples of APIs that achieved a modulated release by
the spray cooling.
3.3. Increase of Stability
The spray cooling technique can also be applied to encapsulate APIs in order to in-
crease stability in adverse conditions, such as the presence of light, oxygen, or unfavourable
pH. Spray cooling can be used to protect probiotic microorganisms from the harsh gas-
trointestinal environment [65]. The use of these bacteria in both food and pharmaceutical
formulations focuses on the need to maintain the viability of these microorganisms during
the formulation of the product and over the storage period. The use of the spray cooling
technique favours the microencapsulation of bacteria mainly because it does not subject the
microorganisms to high temperatures or toxic solvents and lipid matrices are innovative
vehicles to provide protection and the possibility of controlled release to probiotics.
3.4. Flavour Changes
Flavour change is often cited in the literature as one of the main purposes of mi-
cro/nanoencapsulation of APIs. However, few studies involving the spray cooling tech-
nique have been developed for this purpose to date. Some researchers have reported the
microencapsulation of clarithromycin, a macrolide antibiotic with a strong bitter taste [66].
These authors verified the possibility of resorting to microencapsulation techniques with
glyceryl monostearate and aminoalkyl methacrylate copolymer. In this way, it was pos-
sible to prevent the preparation from dissolving in the mouth, having an immediate
release in the gastrointestinal tract, which resulted not only in flavour change, but also in
better bioavailability.
3.5. Encapsulation of Proteins and Peptides
Another little-explored purpose, although very promising, is the microencapsula-
tion of proteins and peptides through the spray cooling technique. Although the use of
these components in pharmaceutical formulations has grown rapidly since 1980 owing
to recombinant DNA technology, the development of delivery systems is still considered
challenging because of the difficulties related to maintaining the stability and therapeutic
action of proteins [67].
Several publications have addressed the use of microencapsulation for the develop-
ment of controlled release systems of proteins and peptides of high therapeutic potential,
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including lactase [68], somatostatine [69], insulin [8], and growing hormones [70]. However,
the choice of technique is limited by the need to maintain the integrity and bioactivity of the
protein, and the use of high temperatures and the use of organic solvents are two factors
that are directly linked to the protein denaturation process [71]. For this aspect, the use of
the spray cooling technique can be advantageous, as there are no solvents or high tempera-
tures. In addition, it is possible to use encapsulating agents of high biocompatibility, such
as triglycerides, in formulations for parenteral release [8].
A study by Maschke et al. obtained positive results regarding the stability of insulin to
the microencapsulation process by spray cooling [8]. The authors used glyceryl tripalmitate
as a matrix material to obtain spherical particles with a smooth surface, with different
concentrations of protein (0.5, 1%, and 2%), and sizes between 182.2 and 315 µm. Insulin
was released for a period of at least 28 days, indicating a possible release up to six months,
with the results being considered satisfactory and promising.
A successful attempt was made to encapsulate a high payload of bovine serum
albumin (10 and 20% w/w) using low-melting lipids [72]. The microparticles produced
were spherical in shape, sizes varied between 150 and 300 µm, and the encapsulation
efficiency was greater than 90%. The studies to verify possible changes in the protein
structure were carried out after encapsulation and the authors found that the structural
integrity was maintained, supporting the conclusion that spray cooling is adequate to
produce particles highly loaded with bovine serum albumin.
The encapsulation procedure of APIs by spray cooling is illustrated in Figure 3.
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4. Conclusions
Spray cooling encapsulation technology has been relatively little explored when
compared with spray drying. However, it has the potential to be an excellent alternative
for the encapsulation of several APIs, with the possibility of administration of particles
through the oral route, providing controlled release, improved stability of the loaded API,
and changing the unpleasant taste and flavour. The spray cooling technique has a high
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potential to overcome many other limitations presented in various industries. In the case
of the pharmaceutical industry, it is possible that this technology is also useful for reducing
the volatility and hygroscopicity of APIs, to facilitate the handling of toxic substances, the
administration of incompatible APIs, and the reduction of gastric irritation. Although not a
recent technique, the significant increase in work involving the micro/nanoencapsulation
of APIs by spray cooling has only happened in the last 10 years. Many of the recently
published works aimed to understand the process variables, as well as to propose changes
in the equipment or procedures, in order to improve the performance in the preparation
of the particles. It is very likely that, with the increased number of studies reporting the
encapsulation of APIs by spray cooling, more researchers will become interested in the
technique, thus enabling new applications in the pharmaceutical area.
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